Heteroaryl dihydroindolones as kinase inhibitors
    4.
    发明授权
    Heteroaryl dihydroindolones as kinase inhibitors 有权
    杂芳基二氢吲哚酮作为激酶抑制剂

    公开(公告)号:US07977351B2

    公开(公告)日:2011-07-12

    申请号:US11687408

    申请日:2007-03-16

    IPC分类号: A61K31/40 C07D471/04

    摘要: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.

    摘要翻译: 本发明提供由下式表示的化合物:其中变量R1,b,R6,Y,Z,X,R和a在说明书中定义。 所述化合物可用于治疗与未调节的酪氨酸激酶信号转导相关的疾病的方法,其中所述疾病选自癌症,血管增生性疾病,纤维化病症,肾小球膜细胞增殖性疾病和代谢疾病。

    Heteroaryl dihydroindolones as kinase inhibitors
    5.
    发明授权
    Heteroaryl dihydroindolones as kinase inhibitors 有权
    杂芳基二氢吲哚酮作为激酶抑制剂

    公开(公告)号:US08455535B2

    公开(公告)日:2013-06-04

    申请号:US13150543

    申请日:2011-06-01

    IPC分类号: A61K31/4015 C07D209/34

    摘要: The present invention provides a compound represented by the formula: wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.

    摘要翻译: 本发明提供由下式表示的化合物:其中环系A和B以及变量R1,b,R6,Y,Z,X,R和a在本说明书中定义。 本发明的化合物可用于治疗与未调节的酪氨酸激酶信号转导相关的疾病的方法,例如癌症,血管增生性疾病,纤维化病症,肾小球膜细胞增殖性疾病和代谢疾病。